Analysts Set Charles River Laboratories International, Inc. (NYSE:CRL) PT at $205.36

Charles River Laboratories International, Inc. (NYSE:CRL) has been assigned an average rating of “Moderate Buy” from the sixteen ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $205.3571.

A number of equities analysts recently commented on CRL shares. Weiss Ratings reiterated a “sell (d)” rating on shares of Charles River Laboratories International in a research report on Monday, April 20th. Evercore reaffirmed an “outperform” rating on shares of Charles River Laboratories International in a research note on Wednesday, April 8th. Mizuho decreased their price target on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating on the stock in a research note on Friday, February 20th. Royal Bank Of Canada assumed coverage on Charles River Laboratories International in a research note on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 price target on the stock. Finally, Robert W. Baird set a $193.00 price target on Charles River Laboratories International in a research note on Thursday, February 19th.

More Charles River Laboratories International News

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Q1 EPS and revenue topped expectations, with EPS of $2.06 vs. a $1.96 consensus and revenue of ~$995.8M above estimates — a near?term positive signal for underlying demand. Charles River Laboratories (CRL) Surpasses Q1 Earnings and Revenue Estimates
• Positive Sentiment: Management and press coverage pointed to steady demand for drug discovery and development services helping the beat — a constructive fundamental sign for the services mix. Charles River beats quarterly estimates on steady demand for drug development services
• Neutral Sentiment: CRL provided FY?2026 guidance of $10.80–$11.30 EPS and revenue roughly $3.8–$3.9B; the range is roughly in line with consensus but revenue guidance sits a touch below some estimates — a mixed signal that limits upside. Charles River Laboratories International, Inc. 2026 Q1 – Results – Earnings Call Presentation
• Negative Sentiment: Margins weakened materially in the quarter (operating/margin compression highlighted by analysts), which offset the top?line beat and is a key reason for investor caution. CRL Q1 Earnings & Revenues Top Estimates, Margins Crash, Stock Down
• Negative Sentiment: An analyst downgrade to “Sell” flagged that organic revenue fell (about a 1.5% organic decline), margins compressed and that longer?term risks (regulatory/AI impacts and valuation concerns after a strong run) justify a more cautious view — adding selling pressure. Charles River Q1 Review: Near-Term Stability But Long-Term Risks (Downgrade)

Hedge Funds Weigh In On Charles River Laboratories International

A number of hedge funds have recently modified their holdings of CRL. Jones Financial Companies Lllp increased its position in shares of Charles River Laboratories International by 167.6% in the first quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock valued at $253,000 after acquiring an additional 1,074 shares during the period. Empowered Funds LLC purchased a new position in shares of Charles River Laboratories International in the first quarter valued at about $418,000. American Century Companies Inc. increased its position in shares of Charles River Laboratories International by 41.9% in the second quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock valued at $830,000 after acquiring an additional 1,616 shares during the period. Brown Advisory Inc. increased its position in shares of Charles River Laboratories International by 5.1% in the second quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock valued at $354,000 after acquiring an additional 114 shares during the period. Finally, California Public Employees Retirement System increased its position in shares of Charles River Laboratories International by 3.9% in the second quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company’s stock valued at $12,837,000 after acquiring an additional 3,198 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $181.95 on Friday. The stock has a market cap of $8.98 billion, a PE ratio of -61.47, a PEG ratio of 2.20 and a beta of 1.44. The company’s fifty day moving average is $170.79 and its 200 day moving average is $183.34. Charles River Laboratories International has a 52 week low of $132.58 and a 52 week high of $228.88. The company has a quick ratio of 1.02, a current ratio of 1.29 and a debt-to-equity ratio of 0.67.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. The company had revenue of $995.83 million for the quarter, compared to analysts’ expectations of $977.46 million. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The firm’s revenue was up 1.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Research analysts anticipate that Charles River Laboratories International will post 10.97 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.